Stephen Salloway, MD, MS, Director of Neurology and the Memory and Aging Program at Butler Hospital and Martin M. Zucker Professor of Psychiatry and Human Behavior and Professor of Neurology at the Warren Alpert Medical School of Brown University, provides an overview of major clinical trials for the treatment of Alzheimer's disease. Dr Salloway highlights the ongoing open-label aducanumab study and upcoming phase III clinical trial studies for lecanemab, donanemab, and ganteneruramb. Over the next few years, Dr Salloway predicts the landscape of Alzheimer's disease treatments will evolve quickly as the drugs begin to hit the market.